Dongyang Sunshine's insulin glargine is about to be approved

On October 25, the NMPA official website indicated that the listing application of Dongyang Sun Pharmaceutical "Insulin Glargine Injection" has entered the administrative approval stage and is expected to be approved in the near future

Insulin glargine is one of the types of centralized insulin procurement.

From: NMPA official website

The development of insulin has gone through three generations: the first-generation insulin-animal insulin, the second-generation insulin-human insulin, and the third-generation insulin-insulin analogues.

The first-generation insulin is derived from animals.

Compared with human insulin, insulin analogues are closer to biological insulin secretion in terms of onset time, peak time, and duration of action

Insulin glargine injection is a new type of insulin analogue with long-acting effect, no peak blood concentration, and a steady lowering of blood sugar in patients.

Among domestic companies, the earliest approval was Gan Li's Chang Xiulin, which was approved for listing in 2005, and then United Laboratories and Tonghua Dongbao were approved in 2016 and 2019, respectively

From: Insight database (http://db.

In the sixth round of centralized insulin procurement of the list announced in September, the products included are all second- and third-generation insulins, grouped by quick-acting, basic and premix

Insulin centralized procurement product list (published version on September 10)